Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.71 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.63 |
| ▸ | KIF11 | P52732 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25293367 | 0.83 | PARP1 (1.00) | PARP1CSNK2A1KIF11RAB9AALDH1A1 | |
| SCHEMBL29203560 | 0.82 | PARP1 (0.68) | PARP1CSNK2A1KIF11ALDH1A1KMT2A | |
| SCHEMBL4725998 | 0.82 | KIF11 (0.84) | PARP1CSNK2A1KIF11RAB9AALDH1A1 | |
| SCHEMBL29708168 | 0.82 | KIF11 (0.84) | PARP1CSNK2A1KIF11RAB9AALDH1A1 | |
| SCHEMBL938618 | 0.80 | PARP1 (0.69) | PARP1CSNK2A1KIF11RAB9AALDH1A1 | |
| SCHEMBL31042188 | 0.80 | PARP1 (0.69) | PARP1CSNK2A1KIF11RAB9AALDH1A1 | |
| SCHEMBL25243790 | 0.79 | PARP1 (0.61) | PARP1CSNK2A1KIF11RAB9AALDH1A1 | |
| SCHEMBL25290687 | 0.78 | PARP1 (0.64) | PARP1CSNK2A1KIF11RAB9AALDH1A1 | |
| SCHEMBL30577715 | 0.78 | PARP1 (0.71) | PARP1CSNK2A1KIF11RAB9AALDH1A1 | |
| SCHEMBL1450212 | 0.78 | PARP1 (0.71) | PARP1CSNK2A1KIF11RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024255697-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-12-19 | — | — | WO | disclosed |
| US-20240368169-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4392425-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-117980307-A | Substituted tricyclic compounds as PARP inhibitors and application thereof | 上海瑛派药业有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023025307-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-03-02 | — | — | WO | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168651-B2 | Protein kinase modulators | CYLENE PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | SENHWA BIOSCIENCES, INC. (TW) | 2009-09-24 | — | — | US | disclosed |
| WO-2009108912-A1 | PROTEIN KINASE MODULATORS | CYLENE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368169-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | PARP1, PARP2, PARP11 | PARP1 1/4885CSNK2A1 477/4885KIF11 3787/4885 |
| US-20120208792-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | PARP1 690/4885CSNK2A1 680/4885KIF11 2815/4885 |
| US-20090239859-A1 | PROTEIN KINASE MODULATORS | PIM1, PIM2, PIM3 | PARP1 690/4885CSNK2A1 680/4885KIF11 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.